DOI:
10.1055/s-00000088
TumorDiagnostik & Therapie
LinksClose Window
References
Tutt A, Robson M, Garber JE et al.
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.
Lancet 2010;
376: 235-244
We do not assume any responsibility for the contents of the web pages of other providers.